Reuters logo
BRIEF-Kedrion, Kamada win FDA approval for rabies treatment
August 25, 2017 / 11:08 AM / a month ago

BRIEF-Kedrion, Kamada win FDA approval for rabies treatment

Aug 25 (Reuters) - Kamada Ltd

* Kedrion biopharma and kamada receive fda approval of kedrab™ for post-exposure prophylaxis against rabies infection

* Kedrion biopharma and kamada receive fda approval of kedrab™ for post-exposure prophylaxis against rabies infection

* Kamada ltd - ‍kedrab will launch in u.s. In early 2018​

* Kamada ltd - ‍revenues from the product are not included in guidance of reaching $100 million in total revenue in 2017​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below